Athenagen commences Alzheimers trial - Pharmaceutical Business Review

Athenagen commences Alzheimers trial - Pharmaceutical Business Review: "Athenagen has commenced a phase II study of the its lead compound, GTS-21, in patients with Alzheimer's disease.

GTS-21 has demonstrated memory and cognition enhancement activity in human clinical trials. GTS-21 has been studied in multiple phase I studies in healthy volunteers and one phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated. "